<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:59:28Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4697364" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4697364</identifier><datestamp>2016-05-23</datestamp><setSpec>wtpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9216904</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">2419</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id>
      <journal-title-group>
        <journal-title>Nature genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1061-4036</issn>
      <issn pub-type="epub">1546-1718</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4697364</article-id>
      <article-id pub-id-type="pmcid">PMC4697364</article-id>
      <article-id pub-id-type="pmc-uid">4697364</article-id>
      <article-id pub-id-type="pmid">26595769</article-id>
      <article-id pub-id-type="pmid">26595769</article-id>
      <article-id pub-id-type="doi">10.1038/ng.3451</article-id>
      <article-id pub-id-type="manuscript">ems65773</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Harley</surname>
            <given-names>Margaret E.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Murina</surname>
            <given-names>Olga</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leitch</surname>
            <given-names>Andrea</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Higgs</surname>
            <given-names>Martin R.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bicknell</surname>
            <given-names>Louise S.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="author-notes" rid="FN1">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yigit</surname>
            <given-names>GÃ¶khan</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blackford</surname>
            <given-names>Andrew N.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zlatanou</surname>
            <given-names>Anastasia</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mackenzie</surname>
            <given-names>Karen J.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reddy</surname>
            <given-names>Kaalak</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Halachev</surname>
            <given-names>Mihail</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McGlasson</surname>
            <given-names>Sarah</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reijns</surname>
            <given-names>Martin A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fluteau</surname>
            <given-names>Adeline</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin</surname>
            <given-names>Carol-Anne</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sabbioneda</surname>
            <given-names>Simone</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elcioglu</surname>
            <given-names>Nursel H.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>AltmÃ¼ller</surname>
            <given-names>Janine</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thiele</surname>
            <given-names>Holger</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Greenhalgh</surname>
            <given-names>Lynn</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chessa</surname>
            <given-names>Luciana</given-names>
          </name>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maghnie</surname>
            <given-names>Mohamad</given-names>
          </name>
          <xref ref-type="aff" rid="A12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salim</surname>
            <given-names>Mahmoud</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bober</surname>
            <given-names>Michael B.</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>NÃ¼rnberg</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jackson</surname>
            <given-names>Stephen P.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="aff" rid="A14">14</xref>
          <xref ref-type="aff" rid="A15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hurles</surname>
            <given-names>Matthew E.</given-names>
          </name>
          <xref ref-type="aff" rid="A15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wollnik</surname>
            <given-names>Bernd</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>Grant S.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jackson</surname>
            <given-names>Andrew P.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>MRC Human Genetics Unit, IGMM, University of Edinburgh, Edinburgh, EH4 2XU, UK
</aff>
      <aff id="A2"><label>2</label>Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
</aff>
      <aff id="A3"><label>3</label>Institute of Human Genetics, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
</aff>
      <aff id="A4"><label>4</label>Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany
</aff>
      <aff id="A5"><label>5</label>Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany
</aff>
      <aff id="A6"><label>6</label>The Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, UK
</aff>
      <aff id="A7"><label>7</label>Istituto di Genetica Molecolare, CNR, 27100 Pavia, Italy
</aff>
      <aff id="A8"><label>8</label>Department of Pediatric Genetics, Marmara University Pendik Hospital, Istanbul, Turkey
</aff>
      <aff id="A9"><label>9</label>Cologne Center for Genomics (CCG), University of Cologne, 50931 Cologne, Germany
</aff>
      <aff id="A10"><label>10</label>Cheshire and Merseyside Clinical Genetics Service, Liverpool Womenâs Hospital, Liverpool, L12 2AP, UK
</aff>
      <aff id="A11"><label>11</label>Department of Clinical and Molecular Medicine, University Sapienza, A.O.S. Andrea, I-00189 Roma, Italy
</aff>
      <aff id="A12"><label>12</label>Department of Pediatrics, IRCCS, Giannina Gaslini, University of Genova, 16147 Genova, Italy
</aff>
      <aff id="A13"><label>13</label>Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware 19803, USA
</aff>
      <aff id="A14"><label>14</label>Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QN, UK
</aff>
      <aff id="A15"><label>15</label>Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK
</aff>
      <aff id="A16"><label>16</label>Institute of Human Genetics, University Medical Centre GÃ¶ttingen, 37073 GÃ¶ttingen, Germany
</aff>
      <author-notes>
        <corresp id="CR1">Correspondence to APJ, <email>andrew.jackson@igmm.ed.ac.uk</email>, GSS, <email>g.s.stewart@bham.ac.uk</email>, or BW, <email>bwollnik@uni-koeln.de</email></corresp>
        <fn fn-type="present-address" id="FN1">
          <label>17</label>
          <p id="P1">Present address: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>13</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>5</month>
        <year>2016</year>
      </pub-date>
      <volume>48</volume>
      <issue>1</issue>
      <fpage>36</fpage>
      <lpage>43</lpage>
      <!--elocation-id from pubmed: 10.1038/ng.3451-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P4">DNA lesions encountered by replicative polymerases threaten genome stability and cell cycle progression. Here we report the identification of mutations in <italic>TRAIP</italic>, encoding an E3 RING ubiquitin ligase, in patients with microcephalic primordial dwarfism/Seckel syndrome. We establish that TRAIP relocalizes to sites of DNA damage where it is required for optimal phosphorylation of H2AX and RPA2 during S-phase in response to UV irradiation, as well as fork progression through UV-induced DNA lesions. TRAIP is necessary for efficient cell cycle progression and mutations in TRAIP therefore limit cellular proliferation, providing a potential mechanism for microcephaly and dwarfism phenotypes. Human genetics thus identifies TRAIP as a novel component of the DNA damage response to replication-blocking DNA lesions.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S1">
      <title>INTRODUCTION</title>
      <p id="P5">The rapid cellular response to genomic insults is facilitated by signaling cascades which utilize diverse post-translational modifications, particularly ubiquitylation and phosphorylation<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. Mutations in genes encoding many components of DNA damage response (DDR) signaling pathways have been identified in human disease<sup><xref rid="R1" ref-type="bibr">1</xref></sup>, reflecting the central importance of DNA repair in maintaining cellular homeostasis. Mutations in DDR genes have been associated with increased cancer predisposition, immunodeficiency, premature ageing and neurodegeneration<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup>. Growth restriction and microcephaly are also features of certain DNA repair disorders<sup><xref rid="R5" ref-type="bibr">5</xref>-<xref rid="R9" ref-type="bibr">9</xref></sup>. Microcephalic primordial dwarfism (MPD) represents a group of single gene disorders<sup><xref rid="R10" ref-type="bibr">10</xref></sup> typically inherited as autosomal recessive traits, that includes Seckel syndrome<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup>, Microcephalic Osteodysplastic Primordial Dwarfism (MOPD) syndromes<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> and Meier-Gorlin syndrome<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup>. In MPD, growth is restricted prenatally and remains severely restricted postnatally, resulting in an adult height as short as 1 meter<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. Marked reduction in brain size, manifesting as microcephaly, distinguishes MPD from other forms of dwarfism, and mutations in genes encoding components of key cellular processes, including centrosome biogenesis, mitotic spindle function, replication licensing and DNA damage repair, have been identified in these disorders<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. Particularly, multiple components of ATR-dependent DDR signaling have been implicated in Seckel syndrome and MOPD II, including mutations in <italic>ATR</italic>, <italic>ATRIP</italic>, <italic>RBBP8</italic> (encoding CtIP) and <italic>PCNT</italic><sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>.</p>
      <p id="P6">To identify further primordial dwarfism genes relevant to cell cycle and DNA repair processes, we performed whole-exome sequencing (WES) on a group of primordial dwarfism patients. Here, we report the identification of <italic>TRAIP</italic> as a novel human disease-associated gene, and implicate the protein it encodes in regulating the DNA damage response to genotoxic lesions during replication.</p>
    </sec>
    <sec sec-type="results" id="S2">
      <title>RESULTS</title>
      <sec id="S3">
        <title><italic>TRAIP</italic> is a novel gene mutated in primordial dwarfism</title>
        <p id="P7">We performed WES to establish a molecular diagnosis for a child with severe microcephalic primordial dwarfism. After filtering to remove common variants (minor allele frequency (MAF) &gt; 0.005), analysis under a recessive inheritance model identified a homozygous nonsense mutation in <italic>TRAIP</italic>, c.553C&gt;T, resulting in a premature stop codon, p.Arg185* (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). Sanger sequencing confirmed the presence of this mutation and its appropriate segregation in the family, with both parents being heterozygous carriers. The variant was not detected on sequencing of 380 control chromosomes, nor was it present in 1000 Genomes, EVS or EXaC public variant databases, in keeping with it being a rare recessive pathogenic mutation. Sanger resequencing of the coding exons and splice junctions of <italic>TRAIP</italic> in 262 primary microcephaly and primordial dwarfism patients identified a second patient, homozygous for the same mutation, p.Arg185*. Notably the two patients were born to non-consanguineous parents and originated from different countries with the families having no known relationship. However, high density genome-wide SNP genotyping demonstrated regions of homozygosity surrounding TRAIP in both patients of 4.6 and 8.4Mb respectively, consistent with unrecognized parental relatedness in each family (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1a</xref>). As well, analysis of genome-wide SNP genotype data using FEstim<sup><xref rid="R20" ref-type="bibr">20</xref></sup> provided an inbreeding coefficient estimate of 0.003 for P2, equivalent to the inbreeding coefficient of 3<sup>rd</sup> cousin parents and also consistent with unknown parental consanguinity in this family (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1b</xref>). Furthermore a 4.3 Mb homozygous haplotype was shared between P1 and P2 for the region immediately surrounding TRAIP, signifying a distant familial link with shared ancestry many generations previously despite their geographical separation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1a</xref>).</p>
        <p id="P8">Additional WES on a cohort of patients with a presumptive diagnosis of Seckel syndrome (n=28), identified a further consanguineous family with a different mutation in <italic>TRAIP</italic>. In this family, a homozygous missense mutation was identified, c.52C&gt;T, resulting in an arginine to cysteine substitution at codon 18 (p.Arg18Cys) (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). This highly conserved residue (<xref ref-type="fig" rid="F1">Fig. 1b</xref>) lies within a RING domain, with the mutation resulting in a large physiochemical change, predicted bioinformatically to be deleterious (Alamut, Interactive Biosoftware Inc). The addition of a further cysteine residue is thought likely to be structurally deleterious, given that RING domains are defined by a specific motif of cysteine and histidine residues that bind zinc divalent cations to establish their tertiary structure<sup><xref rid="R21" ref-type="bibr">21</xref></sup>.</p>
        <p id="P9">The clinical phenotype of all three patients was remarkably similar (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD2">Supplementary Note</xref>). They shared almost identical growth parameters, with global growth failure of prenatal onset and extreme disproportionate microcephaly (<xref ref-type="fig" rid="F1">Fig. 1c</xref>, <xref ref-type="table" rid="T1">Table 1</xref>). Neuroimaging demonstrated reduced cerebral cortical size with simplified gyral folding (<xref ref-type="fig" rid="F1">Fig. 1d</xref>). Craniofacial similarities included a narrow elongated face and micrognathia (<xref ref-type="fig" rid="F1">Fig. 1e</xref>). Additionally, significant morbidity from infections was evident. Patient 1 (P1) and Patient 2 (P2) had frequent lower respiratory tract infections, with P1 dying of respiratory failure aged 10 years as a result of chronic lung disease. Furthermore, P1 had two siblings who died in early infancy<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. However, aside from P2 who had a persistent lymphopenia, there was no evidence of adaptive immune deficits on clinical investigation.</p>
        <p id="P10">On the basis of the mutations identified and phenotypic similarities between patients, we concluded that <italic>TRAIP</italic> was a novel gene associated with primordial dwarfism. TRAIP (TNF receptor associated factor (TRAF)-interacting partner; TRIP; RNF206) is a RING domain-type E3 ubiquitin ligase<sup><xref rid="R23" ref-type="bibr">23</xref></sup> originally identified as a negative regulator of innate immune signaling<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. As it ubiquitylates TBK1<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, a key transducer of Toll-receptors and RIG-I, this could explain the recurrent respiratory illnesses in the patients; however the mechanistic basis for the primordial dwarfism phenotype was less evident. Therefore we proceeded to investigate the functional basis for the growth-related phenotypes.</p>
      </sec>
      <sec sec-type="subjects" id="S4">
        <title>TRAIP protein levels are markedly depleted in patient cells</title>
        <p id="P11">We obtained cell lines from all three patients and characterized these to confirm the deleterious effect of mutations on the TRAIP protein. The Arg185* mutation introduces a premature stop codon in exon 7 and would be expected to cause nonsense-mediated decay of the <italic>TRAIP</italic> transcript. RT-PCR was therefore performed on RNA extracted from patient cells to assess transcript levels. This demonstrated marked reduction in <italic>TRAIP</italic> mRNA both in the immortalized lymphoblastoid cell line from P1 and a primary fibroblast cell line from P2 (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). Notably, low levels of residual full-length mRNA as well as alternatively spliced transcripts were evident. Cloning and sequencing of these RT-PCR products demonstrated that the latter included transcripts that are predicted to produce in-frame deletions of the TRAIP protein of 37 or 99 amino acids (<xref ref-type="fig" rid="F2">Fig. 2a</xref>).</p>
        <p id="P12">Immunoblotting was next performed to establish the consequence of the mutation at the protein level. TRAIP protein levels were greatly reduced in both patient cell lines P1 and P2 carrying the Arg185* mutation (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). A TRAIP protein of comparable size (47 kDa) to wild-type TRAIP (53 kDa) was only detectable on prolonged immunoblot exposure (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>) while a truncated protein isoform of 184 amino acids was not observed, despite the polyclonal antibody (raised against residues 1-270) being able to efficiently detect both <italic>in vitro</italic> synthesized truncated and full-length proteins (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). In conjunction with RT-PCR findings, detection of residual TRAIP protein expression suggests that the mutation is a severe hypomorph, likely compromising, but not completely abrogating TRAIP cellular function. Consistent with this, a knockout mouse model established that <italic>Traip</italic> is essential for early embryonic development, with embryonic lethality seen at gastrulation and a reduction in cell number and embryo growth occurring as early as E5.5<sup><xref rid="R26" ref-type="bibr">26</xref></sup>.</p>
        <p id="P13">The Arg18Cys mutation had no effect on transcript levels (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>), but also resulted in marked reduction of TRAIP protein levels in primary fibroblasts derived from patient P3 (<xref ref-type="fig" rid="F2">Fig. 2b</xref>), probably reflecting reduced protein stability resulting from the missense mutation. We therefore concluded that patient TRAIP mutations would likely lead to substantial impairment of its cellular E3 ligase activity through depletion of overall protein levels.</p>
      </sec>
      <sec id="S5">
        <title>TRAIP localizes to sites of UV-induced DNA damage</title>
        <p id="P14">Phenotypically, TRAIP patients were reminiscent of individuals with Seckel syndrome that have defects in ATR pathway signaling<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup>, particularly with their disproportionately reduced head size. We therefore postulated that TRAIP could be a DDR protein acting in this pathway. Consistent with this, live-imaging of GFP-TRAIP protein demonstrated rapid re-localization from a pan-nuclear distribution to sites of DNA damage after UV laser microirradiation, irrespective of addition of BrdU as a DNA damage sensitizer (<xref ref-type="fig" rid="F3">Fig. 3a</xref>). Colocalization was observed both with Î³H2AX and RFP-PCNA (<xref ref-type="fig" rid="F3">Fig. 3b</xref>). Proximity ligation assays (PLA) detected GFP-TRAIP in close proximity (&lt;40 nm) to PCNA in undamaged cells, suggesting it can be present at replication foci in undamaged cells. This association was substantially enriched after UV-C irradiation (<xref ref-type="fig" rid="F3">Fig. 3c, d</xref>, p&lt; 0.001), consistent with TRAIP localizing with PCNA at sites of DNA damage. Relocalisation of TRAIP to sites of UV-induced DNA damage was confirmed using localized UV-C irradiation through 3 Î¼m isopore membrane filters, after which GFP-TRAIP was detected in irradiated regions, along with multiple DNA damage repair markers, including Î³H2AX and RPA2 (<xref ref-type="fig" rid="F3">Fig. 3e</xref>). Notably, TRAIP was a highly significant hit in a recently reported high-throughput mass spectroscopy screen for proteins recruited to replication blocking DNA lesions<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. As well as re-localizing to DNA damage sites, we also noted that TRAIP protein levels were regulated by DNA damage, with proteasome-mediated degradation observed at later time points after UV treatment (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 5</xref>), similar to certain DDR proteins involved in repair of UV lesions<sup><xref rid="R28" ref-type="bibr">28</xref></sup>.</p>
      </sec>
      <sec id="S6">
        <title>TRAIP is required for RPA2 and H2AX phosphorylation in S-phase</title>
        <p id="P15">To assess whether TRAIP was a novel component of ATR-dependent DDR signaling, siRNA-depleted HeLa cells were irradiated with 10 J/m<sup>2</sup> UV and a time course was performed to monitor activation of this signaling pathway. Unlike ATR/ATRIP deficient cells<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup>, ATR-mediated phosphorylation of the downstream kinase CHK1 was not impaired by TRAIP depletion (<xref ref-type="fig" rid="F4">Fig. 4a</xref>). Additionally, phosphorylation of the ATR substrates NBS1, SMC1 and Ser33-RPA2, as well as the activation of ATM and DNA-PK were also unaffected by TRAIP knockdown (<xref ref-type="fig" rid="F4">Fig. 4a</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6a, b</xref>). However, a striking reduction in phosphorylation of Ser4/Ser8-RPA2 and H2AX was seen in HeLa cells after TRAIP siRNA and in patient fibroblasts (<xref ref-type="fig" rid="F4">Fig. 4b-e</xref>). Complementation of TERT-immortalized P2 fibroblasts (P2<sup>TERT</sup>) by retroviral transduction of wild-type TRAIP (P2<sup>TERT+TRAIP</sup>) restored RPA2/H2AX phosphorylation to normal levels after UV-C irradiation in P2<sup>TERT+TRAIP</sup> cells, confirming that these phosphorylation defects were directly due to loss of TRAIP (<xref ref-type="fig" rid="F4">Fig. 4f</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6c</xref>). Overall, phosphorylation of other ATR, ATM and DNA-PK substrates was comparable between P2<sup>TERT</sup> and P2<sup>TERT+TRAIP</sup> cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6d</xref>). Given this and the normal level of DNA damage-induced phosphorylation of multiple downstream substrates of ATR in siTRAIP-depleted cells, along with a normal G2/M checkpoint in response to UV irradiation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6e</xref>), we concluded that TRAIP deficiency did not give rise to a general defect in ATR signaling, but rather compromised phosphorylation of RPA and H2AX following the induction of UV damage.</p>
        <p id="P16">Since DNA damage response to UV lesions occurs throughout the cell cycle, we next investigated when TRAIP is required to promote RPA2 and H2AX phosphorylation. Using quantitative immunofluorescence, we found that Ser4/Ser8-RPA2 and H2AX phosphorylation induced by UV-C exposure was significantly reduced in EdU-labeled TRAIP patient P2<sup>TERT</sup> cells but not in EdU-negative cells, indicating that TRAIP is specifically required during S-phase for optimal DNA damage- dependent phosphorylation of these proteins (<xref ref-type="fig" rid="F4">Fig. 4g</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 7</xref>). Given that pSer4/Ser8- RPA2 has been associated with the resection of DNA double strand breaks (DSBs), a process that may occur when replication forks encounter UV lesions during S-phase, we considered whether differences in DSBs in patient cells could account for the altered RPA2/H2AX phosphorylation. To assess this, we performed neutral comet assays, which demonstrated equal levels of DSBs in TRAIP patient and control primary fibroblast cell lines after UV-irradiation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8</xref>). This indicated that reduced RPA2/H2AX phosphorylation was not a consequence of altered frequency of DSB formation. We therefore concluded that TRAIP is required for optimal H2AX and RPA2 phosphorylation in response to UV-induced damage encountered in S-phase.</p>
      </sec>
      <sec id="S7">
        <title>Loss of TRAIP impairs cellular proliferation</title>
        <p id="P17">We next considered how <italic>TRAIP</italic> mutations might reduce organism growth. Many primordial dwarfism genes are thought to cause reduced size through lowering the efficiency of cellular proliferation<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. As TRAIP is required for efficient cell proliferation both in human primary cells and during mammalian development<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup>, we assessed the consequences of these mutations on growth rates of primary patient cell lines. We found that doubling times of patient fibroblasts (P2 and P3) were significantly slower than passage-matched control fibroblasts (<xref ref-type="fig" rid="F5">Fig. 5a, c</xref>). Furthermore, this growth defect was complemented by retroviral transduction of patient cells with wild-type TRAIP (<xref ref-type="fig" rid="F5">Fig. 5b</xref>), demonstrating that impaired proliferation was a direct consequence of TRAIP loss in patient cells, and indicating that prolonged cell cycle likely underlies the patient dwarfism phenotype.</p>
        <p id="P18">To further characterize these cell cycle effects, we performed BrdU-pulse chase flow cytometry time courses using isogenic systems. Both TRAIP-depleted HeLa cells (<xref ref-type="fig" rid="F5">Fig. 5d</xref>) and P2<sup>TERT</sup> patient cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 9b, c</xref>) retained higher 4n DNA content at later time points than matched controls (p = 0.0012, p=0.0135, respectively). This could not be accounted for by an increased percentage of mitotic cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 9a</xref>), and therefore represented an increase in late S-phase and/or G2 cells consistent with a replicative origin for the cell cycle delay.</p>
        <p id="P19">To gain a further understanding of TRAIPâs role during replication, we then examined replication fork dynamics in patient cells by DNA fiber analysis in patient cells. Replication fork velocity, inter-origin distance and fork stalling (1<sup>st</sup> label termination events) were not significantly altered in untreated TRAIP patient cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10</xref>), suggesting that TRAIP deficiency does not result in significant global DNA replication defects. Given that TRAIP is required for efficient progression through S-phase and S-phase-specific alterations in RPA2/H2AX phosphorylation after DNA damage induction, we postulated that TRAIP is instead required when the replication fork encounters genotoxic lesions. Consistent with this, following UV irradiation TRAIP patient cells exhibited significantly increased levels of fork stalling (<xref ref-type="fig" rid="F6">Fig. 6a</xref>), and consequently substantially reduced levels of ongoing replicating forks. Moreover, while overall fork velocities were slowed in TRAIP patient cells after UV-C irradiation at rates comparable to control cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11a</xref>), substantial fork asymmetry in TRAIP-deficient cells was observed (<xref ref-type="fig" rid="F6">Fig. 6b, c</xref>), indicative of a problem with fork progression past bulky UV adducts. Importantly, P2<sup>TERT+TRAIP</sup> complemented cells exhibited normal levels of fork stalling (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11b</xref>) and fork symmetry following UV-C irradiation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11c</xref>), establishing that TRAIP was specifically required to prevent fork stalling at UV lesions. Notably, levels of new origin firing were not increased in UV-C treated patient fibroblasts (<xref ref-type="fig" rid="F6">Fig. 6a</xref>), indicating that the ATR-dependent intra-S-phase checkpoint remained intact. In contrast to UV, replication stress induced by low dose aphidicolin, or treatment with a cross-link inducing agent, mitomycin C (MMC), did not result in increased fork asymmetry in TRAIP patient cells compared with control cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11c-e</xref>). Likewise, MMC treatment did not cause increased fork stalling in TRAIP-deficient cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11c, d</xref>). Normal levels of fork recovery were also seen following replication fork stalling after hydroxyurea (HU) treatment (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 12</xref>), establishing that fork stability and replication restart are not generally impaired in TRAIP-deficient cells. Therefore, rather than a general requirement to promote genome replication under conditions of replication stress, TRAIP appears to have a role ensuring fork progression past bulky polymerase-stalling DNA lesions such as UV-photo-products.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="S8">
      <title>DISCUSSION</title>
      <p id="P20">Here, we report the identification of <italic>TRAIP</italic> as a human disease-associated gene and implicate it in DNA damage response to genotoxic lesions during genome replication. DNA damage encountered during S-phase is especially problematic, with substantial risks of mutation and/or genomic rearrangements arising from replication intermediates. Hence, multiple cellular mechanisms are employed to ensure replication fork stability and appropriate repair of DNA lesions<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. Given our data demonstrating increased fork stalling and asymmetry following exposure to UV, but not HU, aphidicolin or MMC, TRAIP is likely to promote repair or bypass of replication blocking lesions induced by UV, rather than playing a general role in stabilizing or promoting restart of stalled replication forks.</p>
      <p id="P21">A role for TRAIP in promoting translesion synthesis (TLS) has been raised by a developmental study of the Drosophila ortholog <italic>nopo</italic> which reported polyubiquitylation of DNA polymerase Î· (Pol Î·) <sup><xref rid="R31" ref-type="bibr">31</xref></sup>. However, the functional relevance of this observation is unclear since experiments were carried out in the absence of UV-induced damage. As well, Pol Î· undergoes active deubiquitylation in mammalian cells after UV irradiation to promote its recruitment to repair sites<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. The patient phenotype is also inconsistent with a role for TRAIP in TLS, as it is distinct from Xeroderma-Pigmentosum-variant (XP-V)<sup><xref rid="R33" ref-type="bibr">33</xref></sup> that results from Pol Î· mutations<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup>. XP-V manifests as freckling, increased sun sensitivity and skin cancer, rather than prenatal onset growth failure and microcephaly. TRAIP patients lack such dermatological features and cancer predisposition has not been observed, although all are still children. Furthermore, TRAIP cells do not exhibit the increased ATR pathway activation seen in XP-V cells<sup><xref rid="R36" ref-type="bibr">36</xref></sup>. Hence, TRAIP more likely acts in a parallel, TLS-independent process, to overcome UV-C replication blocking lesions. TRAIP could instead be involved in a homologous recombination dependent mechanism to resolve such replication blocks, particularly given the role of RPA hyperphosphorylation in recruiting Rad51 after replication fork arrest<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. Decreased RPA2 (and H2AX) phosphorylation might directly account for impaired fork progression at such UV-induced lesions, although how TRAIP promotes H2AX and RPA phosphorylation remains to be defined. TRAIP could act either by positively regulating a DDR protein kinase at UV-induced damage sites, or suppressing PP2A or PP4 protein phosphatases that dephosphorylate Î³H2AX and pSer4/Ser8-RPA2<sup><xref rid="R38" ref-type="bibr">38</xref>-<xref rid="R41" ref-type="bibr">41</xref></sup>.</p>
      <p id="P22">Ubiquitylation regulates many key DNA damage response processes<sup><xref rid="R2" ref-type="bibr">2</xref></sup>, with several DDR-associated E3 ubiquitin ligases, including BRCA1<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup>, RNF168<sup><xref rid="R44" ref-type="bibr">44</xref></sup> and FANCL<sup><xref rid="R45" ref-type="bibr">45</xref></sup> implicated in human disease. The identification of additional TRAIP ubiquitylation substrates will be important to understand the disease process, and will likely provide further insights into its role at replication blocking lesions. It also remains to be formally established if its DNA repair/replication roles are dependent on a functional RING domain, as TRAIP could have E3 ligase-independent functions.</p>
      <p id="P23">Total cell number is the predominant determinant of size in mammals<sup><xref rid="R46" ref-type="bibr">46</xref></sup>. Similarly, reduced cellularity from early development is believed to cause primordial dwarfism<sup><xref rid="R10" ref-type="bibr">10</xref></sup>, with decrease in neuronal number generated during neurogenesis underlying the microcephaly. The DNA replication machinery is implicated in other forms of microcephalic dwarfism<sup><xref rid="R47" ref-type="bibr">47</xref>-<xref rid="R49" ref-type="bibr">49</xref></sup> and replication stress during embryonic development underlies Seckel syndrome due to <italic>ATR</italic> mutations<sup><xref rid="R50" ref-type="bibr">50</xref></sup>. Therefore, perturbed cell cycle progression as a consequence of replication blocking lesions could account for the microcephaly and dwarfism present in our TRAIP patients. For the cellular studies described here, UV-C irradiation was used to generate replication-blocking lesions. Most commonly these will be bulky cyclobutane pyrimidine dimers, which are unlikely to be encountered in the embryo. However during development, different replication blocking DNA lesions are present, with potential candidates being those arising from oxidative damage<sup><xref rid="R51" ref-type="bibr">51</xref></sup> or aldehydes<sup><xref rid="R52" ref-type="bibr">52</xref></sup>. Therefore endogenous DNA lesions may pose difficulties for TRAIP-deficient cells during development, and result in depleted overall cell numbers (Model, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 13</xref>) that underlies other microcephalic dwarfism disorders <sup><xref rid="R48" ref-type="bibr">48</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R53" ref-type="bibr">53</xref></sup>.</p>
      <p id="P24">In summary, we identify <italic>TRAIP</italic> as a novel disease-associated gene, and through investigating the cellular basis of the human phenotype establish its involvement in DDR. TRAIP promotes H2AX and RPA2 phosphorylation following replication-associated DNA damage, and assists fork progression at UV-induced replication blocking lesions. Developmentally viable alleles identified through human genetics will facilitate future studies investigating its roles during embryogenesis, while identification of TRAIP substrates and mechanistic studies of its role in response to DNA lesions encountered during DNA synthesis, will provide further insight into the key cellular processes maintaining genome stability during replication.</p>
    </sec>
    <sec sec-type="methods" id="S9" specific-use="web-only">
      <title>ONLINE METHODS</title>
      <sec sec-type="subjects" id="S10">
        <title>Research subjects</title>
        <p id="P25">Genomic DNA from the affected children and family members was extracted from peripheral blood using standard methods or saliva samples using Oragene collection kits according to the manufacturerâs instructions. Informed consent was obtained from all participating families and the studies were approved by the ethics review boards, the Scottish Multicentre Research Ethics Committee (04:MRE00/19) and the Ethics Committee of the University Hospital Cologne, Germany. Parents provided written consent for the publication of photographs of the affected individuals.</p>
      </sec>
      <sec id="S11">
        <title>Exome sequencing and haplotype analysis</title>
        <p id="P26">Exome sequencing of genomic DNA and variant filtering was performed as described previously<sup><xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R55" ref-type="bibr">55</xref></sup>. Cohort resequencing was performed by Sanger sequencing of PCR products representing all coding exons of TRAIP (primer sequences available on request), with variant calling using MutationSurveyor (SoftGenetics Inc). Haplotype analysis was undertaken by SNP genotyping both patients using Affymetrix CytoScan 750K arrays. Genotypes were generated using Affymetrix Genotyping Console software and examined manually.</p>
        <p id="P27">Inbreeding coefficients for P1 and P2 were estimated using FEstim<sup><xref rid="R20" ref-type="bibr">20</xref></sup>, using SNP genotypes with confidence scores &lt; 10<sup>â4</sup>, after linkage disequilibrium (LD) pruning using PLINK v1.90b3o (64-bit) <sup><xref rid="R56" ref-type="bibr">56</xref></sup>. Runs of homozygosity (ROH) were also used to calculate F<sub>ROH</sub> using PLINK, as described previously<sup><xref rid="R57" ref-type="bibr">57</xref>,<xref rid="R58" ref-type="bibr">58</xref></sup>. In brief, SNPs were excluded with NoCall frequency above 3% across individuals or with a minor allele frequency (MAF) &lt; 5%. ROH were defined as runs of at least 50 consecutive homozygous SNPs spanning at least 1.5 Mb, with less than a 1 Mb gap between adjacent ROHs and a density of SNP coverage within the ROH of no more than 50 Kb/SNP, with at most one heterozygous SNP and five NoCalls allowed per window.</p>
      </sec>
      <sec id="S12">
        <title>Cell culture</title>
        <p id="P28">Lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 supplemented with 15% fetal bovine serum, L-glutamine and penicillin/streptomycin antibiotics in 5% CO<sub>2</sub> and normoxic conditions. Lymphoblastoid cell lines were generated in house from peripheral blood samples by EBV transformation using standard methods. Dermal primary fibroblasts were grown from skin punch biopsies in AmnioMax medium (Life Technologies) and then maintained in Dulbeccoâs MEM (modified Eagleâs medium; DMEM) supplemented with 10% fetal bovine serum, 5% L-glutamine and 5% penicillin/streptomycin antibiotics in 5% CO<sub>2</sub> and hypoxic 3% O<sub>2</sub> conditions. Patient cell lines were validated using Sanger sequencing and immunoblotting. HeLa cells were maintained in DMEM supplemented with 10% fetal bovine serum, 5% L-glutamine and 5% penicillin/streptomycin antibiotics in 5% CO<sub>2</sub> and normoxic conditions. HeLa (ATCC), U2OS and MRC5 (GDSC, Sussex) cells were cultured in DMEM supplemented with 10% fetal bovine serum, 5% L-glutamine and 5% penicillin/streptomycin antibiotics.</p>
        <p id="P29">Stable cell lines were generated by Flp recombinase-mediated integration using HeLa-Flp-In T-REx host cells (gift from Stephen Taylor, University of Manchester<sup><xref rid="R42" ref-type="bibr">42</xref></sup>) transfected with pcDNA5/FRT/TO-EGFP (vector only or EGFP-TRAIP) and pCAGGS-Flp.e (gift from Dirk-Jan Kleinjan, University of Edinburgh). Transfected cells were selected using 5 Î¼g/ml blasticidin and 400 Î¼g/ml hygromycin and the resulting colonies were then expanded for testing. Protein expression was induced with 1 Î¼g/ml tetracycline treatment. HeLa cells expressing RFP-PCNA were a gift from Agata Lichawska and JÃ¶rg Mansfeld, Gurdon Institute. Primary fibroblasts derived from P2 were immortalized with hTERT retroviral supernatant with 4 Î¼g/ml polybrene and infected with pMSCV-vector only or pMSCV-TRAIP. Selection was performed using 750 ng/ml puromycin and 500 Î¼g/ml neomycin. Expression of the protein was verified by Western blot (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6c</xref>). All cell lines were routinely tested for mycoplasma.</p>
      </sec>
      <sec id="S13">
        <title>Cell treatments</title>
        <p id="P30">Plasmids and siRNA oligos were transfected in Opti-MEM reduced serum media using Oligofectamine (Life Technologies) according to the manufacturerâs guidelines. The siRNA oligonucleotide sequences are listed in <xref ref-type="supplementary-material" rid="SD2">Supplementary Table 1a</xref>. Where indicated, cells were treated with 10 Î¼M MG132 (Cayman Chemicals), 10 or 15 J/m<sup>2</sup> UV-C, 2 mM hydroxyurea (Sigma-Aldrich), 0.5 Î¼M aphidicolin (Sigma-Aldrich), 50 ng/ml mitomycin C (Sigma-Aldrich) or 2 mM thymidine (Sigma-Aldrich).</p>
      </sec>
      <sec id="S14">
        <title>RT-PCR</title>
        <p id="P31">Total RNA was extracted from cell lines using the RNeasy kit (Qiagen) according to the manufacturerâs instructions. DNA was removed by treatment with DNase I (Qiagen) and cDNA was generated using random oligomer primers and AMV RT (Roche). The RT-PCR primer pairs used are listed in <xref ref-type="supplementary-material" rid="SD2">Supplementary Table 1b</xref>.</p>
      </sec>
      <sec id="S15">
        <title>Western blot analysis and antibodies</title>
        <p id="P32">Whole cell extracts were obtained by lysis and sonication of cells in UTB buffer (8 M Urea, 50 mM Tris pH 7.5, 150 mM Î²-mercaptoethanol, protease inhibitor cocktail (Roche)) or in NP-40 lysis buffer (50 mM Tris pH 8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% Glycerol, 1 mM DTT, protease inhibitor cocktail (Roche), 1 mM PMSF, phosphatase inhibitors (40 mM NaF, 1 mM sodium orthovanadate)) and analyzed by SDS-PAGE following standard procedures. Protein samples were run on 6-12% acrylamide SDS-PAGE or 4-12% NuPage mini-gels (Life Technologies) and transferred onto nitrocellulose membrane. Immunoblotting was performed using antibodies to RPA2 (Santa Cruz, sc-28709; 1:1000), pS4/S8-RPA2 (Bethyl Laboratories, A300-245A; 1:1000), pS33-RPA2 (Bethyl Laboratories, A300-246A; 1:1000), H2A (Millipore, 07-146; 1:5000), Î³H2AX (Millipore, 05-636; 1:1000), actin (Sigma-Aldrich, A2066; 1:5000), vinculin (Sigma-Aldrich, V9264; 1:1000), pS966-SMC1 (Bethyl Laboratories, A300-050A; 1:1000), SMC1 (Abcam, ab9262; 1:2000), pS343-NBS1 (Cell Signaling Technology, 3001; 1:500), NBS1 (Oncogene, PC269T; 1:500), pS345-CHK1 (Cell Signaling Technology, 2341; 1:500), CHK1 (Santa Cruz, sc-8408; 1:1000), pT68-CHK2 (Cell Signaling, 2661; 1:500) , CHK2 (Santa Cruz, sc-9064; 1:500), pS1981-ATM (Cell Signaling, 4526; 1:500), ATM (Abcam, ab31842; 1:1000), pS2056-DNA-PKcs (Abcam, ab18192; 1:400), DNA-PKcs (Abcam, ab32566; 1:1000), pS824-KAP1 (Bethyl Laboratories, A300-767A; 1:5000), KAP1 (Bethyl Laboratories, A300-274A; 1:10000), CDK1 (Sigma-Aldrich, P7962; 1:1000), cyclin A (Santa Cruz, sc-751; 1:1000), cyclin B1 (Cell Signaling Technology, 4135; 1:1000), pS10-Histone H3 (Millipore, 06-570; 1:1000), Histone H3 (Millipore, 07-690; 1:10,000), FLAG (Agilent, clone M2; 1:1000).</p>
        <p id="P33">TRAIP antibody was generated from recombinant TRAIP protein using pGEX-4T-2-TRIP-N (gift from Robert Geahlen, Purdue University, USA). Antibody was affinity purified from rabbit sera (Eurogentec) and specificity established using patient cell lysates and RNAi.</p>
      </sec>
      <sec id="S16">
        <title>Laser line assay</title>
        <p id="P34">Laser micro-irradiation and live cell imaging were performed as described previously in supplemental methods of ref<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. Plasmids were transfected into U2OS cells using <italic>Trans</italic>IT-LT1 (Mirus Bio), according to the manufacturerâs instructions. Images were acquired using an Olympus FluoView 1000 confocal microscope.</p>
      </sec>
      <sec id="S17">
        <title>Immunofluorescence: GFP-TRAIP localisation</title>
        <p id="P35">MRC5 fibroblasts were transfected with EGFP-TRAIP using Lipofectamine 2000 (Life Technologies) according to the manufacturerâs instructions. The cells were trypsinised and seeded onto coverslips 6 hours post-transfection. The following day, the cells were washed once in warm PBS and treated with 2 mM hydroxyurea for 24 h or irradiated either at 25 J/m<sup>2</sup> for global UV-C irradiation (fluency rate 0.8 J/m<sup>2</sup>/s) or at 120 J/m<sup>2</sup> for local UV-C irradiation through isopore membrane 3 Î¼M filters (Millipore) and fixed 1 h or 1.5 h post UV-C, respectively. Immunofluorescence (IF) was performed as previously described<sup><xref rid="R60" ref-type="bibr">60</xref></sup> with minor modifications. Briefly, the cells were either pre-extracted in CSK100 buffer and then fixed in 4% paraformaldehyde for 15 min at room temperature or fixed first and then permeabilized in 0.5% Triton-X100 in PBS at room temperature for 15 min. Primary and secondary antibodies' incubations were performed in IF buffer (3% BSA in PBS) for 1 hour at room temperature. Primary antibodies: XPC (Santa Cruz, 1:100), PCNA (PC10, Santa Cruz, 1:400), Î³H2AX (Millipore, 1:500), RPA2 (Calbiochem, 1:200); secondary antibodies: Alexa Fluor-594 or Alexa Fluor-488 (Molecular Probes); DAPI 0.4 Î¼g/ml (Vectashield). For EdU detection, cells were pulsed with 20 Î¼M EdU for 20 min and then detected using the Click-iT EdU Imaging kit (Life Technologies) according to the manufacturerâs protocol. Fluorescence images were taken using a Nikon E600 Eclipse microscope equipped with a 60X oil lens, and images were acquired and analysed using Volocity Software v4.1 (Improvision).</p>
      </sec>
      <sec id="S18">
        <title>Proximity ligation assay (PLA)</title>
        <p id="P36">Cells from stable EGFP/ EGFP-TRAIP HeLa Flp-In T-REx cell lines were fixed with methanol at â20 Â°C for 10 min followed by a 5 min extraction in 0.3% Triton-X100 in PBS. Cells were then incubated in anti-PCNA antibody (Santa Cruz, PC10; 1:500) and anti-GFP antibody (Abcam, ab6556; 1:500), and <italic>in situ</italic> proximity ligation was performed using a Duolink Detection Kit in combination with anti-Mouse PLUS and anti-Rabbit MINUS PLA Probes, according to the manufacturerâs instructions (Sigma Aldrich Duolink). Nuclear foci were imaged using a Nikon E600 Eclipse microscope equipped with a 60X oil lens, and images were acquired and analysed using Volocity Software v4.1 (Improvision). The number of nuclear foci/cell was quantified using ImageJ. More than 50 cells were analyzed per experiment per condition.</p>
      </sec>
      <sec id="S19">
        <title>Quantitative immunofluorescence of pSer4/Ser8-RPA2 and Î³H2AX</title>
        <p id="P37">Passage-matched TERT-immortalized fibroblasts were seeded on coverslips, 24 h later damaged with 15 J/m2 UV-C irradiation and left to recover for 4 hours in media containing 10 Î¼M EdU. To remove soluble proteins prior to immunofluorescence, cells were pre-extracted for 10 min on ice with ice-cold buffer (25 mM Hepes 7.4, 50 mM NaCl, 1mM EDTA, 3 mM MgCl<sub>2</sub>, 300 mM sucrose and 0.5% TritonX-100) and then fixed with 4% paraformaldehyde for 15 min. EdU immunolabeling was performed using Click-iT EdU Imaging Kit (Invitrogen, C10337) according to the manufacturerâs protocol. Afterwards cells were stained for pS4/S8-RPA2 (Bethyl Laboratories, A300-245A; 1:1000) or Î³H2AX (Millipore, 05-636; 1:800) and then stained with secondary antibodies conjugated to Alexa Fluor-568 (Life Technologies) and DAPI. For quantification of signal integrated densities, images were visualized using a Zeiss Axioplan 2 microscope with iVision software (BioVision Technologies) and captured using 40X oil-immersion objective. Exposure time, binning, microscope settings and light source intensity were kept constant for all the samples. Nuclei were segmented on the basis of DAPI staining and then signal integrated density of pS4/S8-RPA2 and Î³H2AX staining quantified for each nuclear region using ImageJ software (US National Institutes of Health). More than 50 EdU positive and 150 EdU negative cells were analyzed per experiment per condition.</p>
      </sec>
      <sec id="S20">
        <title>Comet assay</title>
        <p id="P38">Neutral comet assays were carried out using the Trevigen Comet Assay<sup>â¢</sup> electrophoresis kit (4250-050-K) according to manufacturerâs instructions. Briefly, 1Ã10<sup>5</sup> primary fibroblasts were seeded in 6 well plates overnight for approximately 16 hours. Cells were then treated with 15 J/m<sup>2</sup> UV-C and allowed to recover for 4 hours in media. Cells were collected and embedded into low melting agarose on 'comet' slides (Trevigen) and incubated in lysis solution overnight in the dark at 4Â°C. Cells were then electrophoresed in buffer (50 mM Tris pH 9.0, 150 mM sodium acetate) for 45 min at 21 volts at 4Â°C in the dark. Comet slides were immersed in DNA precipitation solution (1 M ammonium acetate, 95% ethanol) for 30 min and 70% ethanol for 30 min at room temperature and dried at 37Â°C for 15 min. Slides were stained in 1x SYBR gold in TE buffer (pH 7.5) for 30 min at room temperature, dried for an additional 15 min at 37Â°C and then visualized with an epifluorescence microscope and analyzed using CaspLab software.</p>
      </sec>
      <sec id="S21">
        <title>FACS analysis</title>
        <p id="P39">Passage-matched TERT-immortalized fibroblasts grown in AmnioMax medium (Life Technologies) or HeLa cells were pulse labeled with 10 Î¼M BrdU for 30 min before fixation with 70% ethanol at â20Â°C for 16 h. Cells were then digested with 1 mg/ml pepsin and denatured with 2 M HCl, before washing with PBS and blocking in 0.5% BSA, 0.5% Tween-20. BrdU labeling was detected using anti-BrdU antibody (Abcam, ab6326; 1:75) and FITC-conjugated anti-rat secondary antibody. DNA content was assessed by staining with 50 Î¼g/ml propidium iodide. Cells were sorted on a BD Biosciences FACS Aria II and data were analyzed using FlowJo software (v7.6.1, Tree Star).</p>
      </sec>
      <sec id="S22">
        <title>Mitotic index of pulse labeled EdU cells</title>
        <p id="P40">HeLa cells were seeded on poly-L-lysine-coated coverslips 48 h after siRNA transfection. The following day, 10 Î¼M EdU was added to the cells for 30 min, washed out with PBS and media replaced. 6 h later cells were fixed using 4% paraformaldehyde and stained for pSer10-Histone H3 (Cell Signalling, 9706; 1:250) and EdU (Click-iT EdU Imaging Kit, Invitrogen, C10337) according to the manufacturerâs protocol. Cells were then stained with secondary antibody conjugated to Alexa Fluor-568 (Life Technologies) and analyzed using a Zeiss Axioplan 2 microscope equipped with a 60X oil-immersion objectives and iVision software (BioVision Technologies).</p>
      </sec>
      <sec id="S23">
        <title>G2/M checkpoint assay</title>
        <p id="P41">A previously established assay was used to determine mitotic cell number after damage-induced checkpoint activation<sup><xref rid="R61" ref-type="bibr">61</xref></sup>. In brief, HeLa cells transfected with RNAi against TRAIP or luciferase (control) for 72 h were treated with 10 J/m<sup>2</sup> UV-C and fixed in 96% ethanol 4 h later. Mitotic cells were determined by pSer10-Histone H3 (Cell Signalling, 9706; 1:250) staining and flow cytometry on a BD Biosciences FACS Aria II.</p>
      </sec>
      <sec id="S24">
        <title>DNA fiber spreading assay</title>
        <p id="P42">Passage-matched primary or TERT-immortalized fibroblasts were pulse labeled with CldU for 20 min, washed with PBS and damaged with 30 J/m<sup>2</sup> UV-C, 2 mM hydroxyurea for 2 h or 0.5 Î¼M aphidicolin before being pulse labeled with IdU for 20 or 40 min as indicated. 0.5 Î¼M aphidicolin was added to the cells for 40 min together with IdU pulse labeling. 50 ng/ml mitomycin C was added to the cells for 24 h before CldU pulse labeling and left on during 20 min CldU and 20 min ldU pulse labeling. Cells were harvested by trypsinization and cell pellets were washed in PBS. 5Ã10<sup>5</sup> cells were lysed directly onto glass slides using spreading buffer (200 mM Tris-HCl pH 7.5, 50 mM EDTA, 0.5% SDS) and fixed in methanol:acetic acid (3:1 ratio). Following 2.5 M HCl denaturation, CldU was detected using rat anti-BrdU (clone BU1/75, ICR1; Abcam, ab6326; 1:750) and IdU was detected using mouse anti-BrdU (clone B44; BD Biosciences, 347583; 1:750). Slides were then fixed in 4% paraformaldehyde before immunostaining with secondary antibodies conjugated to Alexa Fluor-594 or Alexa Fluor-488 (Life Technologies). Labeled DNA fibers were visualized using a Zeiss Axioplan 2 microscope with iVision software (BioVision Technologies). Images were captured using 40X oil-immersion objectives and analyzed using ImageJ software (US National Institutes of Health).</p>
      </sec>
      <sec id="S25">
        <title>In vitro transcription/translation</title>
        <p id="P43">The TnT<sup>Â®</sup> T7 Quick Coupled Transcription/Translation System (Promega) was used to produce FLAG-tagged TRAIP (WT, R18C or R185X) <italic>in vitro</italic> following the manufacturerâs instructions. Briefly, 250 ng of plasmid DNA (pcDNA-based, TRAIP with an N-terminal single FLAG epitope) in 2.25 Î¼l of water was mixed with 10 Î¼l TNT<sup>Â®</sup> T7 Quick Master Mix, 0.25 Î¼l of 1 mM methionine and incubated for 90 min at 30Â°C. For immunoblotting 1 Î¼l of each reaction was separated by SDS-PAGE on 4-12% NuPAGE gels (Life Technologies), and TRAIP was detected using anti-FLAG or anti-TRAIP antibodies.</p>
      </sec>
      <sec id="S26">
        <title>Statistical analysis</title>
        <p id="P44">Numerical data were analyzed using parametric and nonparametric statistical tests, namely Studentâs <italic>t</italic>-test, ANOVA or Mann Whitney Rank sum test, as indicated. Statistical tests were two-sided unless otherwise stated in figure legend. Significance thresholds are indicated in figure legends.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>Supplementary Figures</label>
        <media xlink:href="NIHMS65773-supplement-Supplementary_Figures.doc" orientation="portrait" xlink:type="simple" id="d37e1190" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD2">
        <label>Supplementary Note &amp; Table</label>
        <media xlink:href="NIHMS65773-supplement-Supplementary_Note___Table.pdf" orientation="portrait" xlink:type="simple" id="d37e1194" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S27">
      <title>ACKNOWLEDGMENTS</title>
      <p>We thank the families and clinicians for their involvement and participation; N. Hastie, W. Bickmore, D. Fitzpatrick, J.-C. Acosta, M. Nowotny, V.Vitart and A. Lehmann for helpful discussions; R. Geahlen (Purdue University, USA), S. Taylor (University of Manchester), D.-J. Kleinjan (University of Edinburgh), A. Lichawska and J. Mansfeld (Gurdon Institute) for their kind gifts of reagents; J. Ding, P. Hari and E. Milz for technical assistance; E. Freyer for assistance with FACS analysis; the IGMM core sequencing service; A. Wheeler and the IGMM imaging facility for assistance with microscopy, E.Maher and A.Pearce for performing SNP genotyping arrays. This work was supported by funding from the Medical Research Council and the European Research Council (ERC, 281847) (A.P.J.), the Lister Institute for Preventative Medicine (A.P.J. and G.S.S.), Medical Research Scotland (L.S.B.), German Federal Ministry of Education and Research (BMBF, 01GM1404) and E-RARE network EuroMicro (B.W), Wellcome Trust (M. Hurles), CMMC (P.N.), Cancer Research UK (C17183/A13030) (G.S.S. and M.R.H), Swiss National Science Foundation (P2ZHP3_158709) (O.M.), AIRC (12710) and ERC/EU FP7 (CIG_303806) (S.S.), Cancer Research UK (C6/A11224) and ERC/EU FP7 (HEALTH-F2-2010-259893) (A.N.B. and S.P.J.).</p>
    </ack>
    <fn-group>
      <fn id="FN3">
        <p id="P45"><bold>ACCESSION CODES and URLs</bold>
</p>
        <p id="P46">Exome sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/">https://www.ebi.ac.uk/ega/</ext-link>), under accession number EGAS00001001501.</p>
      </fn>
      <fn id="FN4">
        <p id="P47"><bold>COMPETING FINANCIAL INTERESTS</bold>
</p>
        <p id="P48">M.E. Hurles is a co-founder, share-holder and consultant to Congenica Ltd, a clinical diagnostics company.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="APP1">
        <title>AUTHOR CONTRIBUTIONS</title>
        <p id="P3">M.E. Hurles, L.S.B., M. Halachev, G.Y., J.A., H.T., P.N., and B.W. performed exome sequencing and analysis. L.S.B., M.E. Harley, G.Y., S.M., and B.W. performed sequencing, genotyping, linkage analysis and other molecular genetics experiments. M.E. Harley, O.M., A.L., M.R.H., A.N.B., A.Z., K.R., M.A.M.R., A.F., C.-A.M., S.S., S.P.J. and G.S.S. designed and performed the cell biology experiments. N.H.E., L.G., L.C., M.M., M.S., M.B.B., K.J.M., and B.W. ascertained subjects, obtained samples and/or assisted with clinical studies. M.E. Harley and A.P.J. wrote the manuscript. The study was planned and supervised by B.W., G.S.S. and A.P.J.</p>
      </app>
    </app-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciccia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elledge</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>The DNA damage response: making it safe to play with knives</article-title>
          <source>Mol Cell</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>179</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">20965415</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Durocher</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Regulation of DNA damage responses by ubiquitin and SUMO</article-title>
          <source>Mol Cell</source>
          <year>2013</year>
          <volume>49</volume>
          <fpage>795</fpage>
          <lpage>807</lpage>
          <pub-id pub-id-type="pmid">23416108</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slatter</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gennery</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Primary immunodeficiencies associated with DNA-repair disorders</article-title>
          <source>Expert Rev Mol Med</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>e9</fpage>
          <pub-id pub-id-type="pmid">20298636</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woods</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>DNA repair disorders</article-title>
          <source>Arch Dis Child</source>
          <year>1998</year>
          <volume>78</volume>
          <fpage>178</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="pmid">9579166</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>German</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients</article-title>
          <source>Am J Hum Genet</source>
          <year>1969</year>
          <volume>21</volume>
          <fpage>196</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">5770175</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>JE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extreme growth failure is a common presentation of ligase IV deficiency</article-title>
          <source>Hum Mutat</source>
          <year>2014</year>
          <volume>35</volume>
          <fpage>76</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">24123394</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Driscoll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ruiz-Perez</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Jeggo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Goodship</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>33</volume>
          <fpage>497</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="pmid">12640452</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogi</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome</article-title>
          <source>PLoS Genet</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>e1002945</fpage>
          <pub-id pub-id-type="pmid">23144622</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Bartek</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The DNA-damage response in human biology and disease</article-title>
          <source>Nature</source>
          <year>2009</year>
          <volume>461</volume>
          <fpage>1071</fpage>
          <lpage>1078</lpage>
          <pub-id pub-id-type="pmid">19847258</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klingseisen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms and pathways of growth failure in primordial dwarfism</article-title>
          <source>Genes Dev</source>
          <year>2011</year>
          <volume>25</volume>
          <fpage>2011</fpage>
          <lpage>2024</lpage>
          <pub-id pub-id-type="pmid">21979914</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majewski</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Goecke</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Studies of microcephalic primordial dwarfism I: approach to a delineation of the Seckel syndrome</article-title>
          <source>Am J Med Genet</source>
          <year>1982</year>
          <volume>12</volume>
          <fpage>7</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">7046443</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Seckel</surname>
              <given-names>HPG</given-names>
            </name>
          </person-group>
          <source>Bird-Headed Dwarfs</source>
          <year>1960</year>
          <publisher-name>S.Karger</publisher-name>
          <publisher-loc>Basel</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majewski</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ranke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schinzel</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Studies of microcephalic primordial dwarfism II: the osteodysplastic type II of primordial dwarfism</article-title>
          <source>Am J Med Genet</source>
          <year>1982</year>
          <volume>12</volume>
          <fpage>23</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">7201238</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majewski</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stoeckenius</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kemperdick</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Studies of microcephalic primordial dwarfism III: an intrauterine dwarf with platyspondyly and anomalies of pelvis and clavicles--osteodysplastic primordial dwarfism type III</article-title>
          <source>Am J Med Genet</source>
          <year>1982</year>
          <volume>12</volume>
          <fpage>37</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">7201239</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bongers</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Meier-Gorlin syndrome: report of eight additional cases and review</article-title>
          <source>Am J Med Genet</source>
          <year>2001</year>
          <volume>102</volume>
          <fpage>115</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">11477602</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gorlin</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Cervenka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Horrobin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Witkop</surname>
              <given-names>CJ</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Malformation syndromes. A selected miscellany</article-title>
          <source>Birth Defects Orig Artic Ser</source>
          <year>1975</year>
          <volume>11</volume>
          <fpage>39</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">819054</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in the Pericentrin (PCNT) Gene Cause Primordial Dwarfism</article-title>
          <source>Science</source>
          <year>2008</year>
          <volume>319</volume>
          <fpage>816</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="pmid">18174396</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffith</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>232</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="pmid">18157127</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qvist</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CtIP Mutations Cause Seckel and Jawad Syndromes</article-title>
          <source>PLoS Genet</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>e1002310</fpage>
          <pub-id pub-id-type="pmid">21998596</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leutenegger</surname>
              <given-names>AL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Using genomic inbreeding coefficient estimates for homozygosity mapping of rare recessive traits: application to Taybi-Linder syndrome</article-title>
          <source>Am J Hum Genet</source>
          <year>2006</year>
          <volume>79</volume>
          <fpage>62</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">16773566</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borden</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Freemont</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>The RING finger domain: a recent example of a sequence-structure family</article-title>
          <source>Curr Opin Struct Biol</source>
          <year>1996</year>
          <volume>6</volume>
          <fpage>395</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="pmid">8804826</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silengo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Del Monaco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Linari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lala</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Low birth-weight, microcephalic malformation syndrome in a 46,XX girl and her 46,XY sister with agonadism: third report of the Kennerknecht syndrome or autosomal recessive Seckel-like syndrome with previously undescribed genital anomalies</article-title>
          <source>Am J Med Genet</source>
          <year>2001</year>
          <volume>101</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">11424145</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Besse</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Darnay</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>TRAF-interacting protein (TRIP) is a RING-dependent ubiquitin ligase</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2007</year>
          <volume>359</volume>
          <fpage>660</fpage>
          <lpage>664</lpage>
          <pub-id pub-id-type="pmid">17544371</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation</article-title>
          <source>J Exp Med</source>
          <year>1997</year>
          <volume>185</volume>
          <fpage>1275</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="pmid">9104814</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1</article-title>
          <source>J Exp Med</source>
          <year>2012</year>
          <volume>209</volume>
          <fpage>1703</fpage>
          <lpage>1711</lpage>
          <pub-id pub-id-type="pmid">22945920</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>ES</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early embryonic lethality caused by targeted disruption of the TRAF-interacting protein (TRIP) gene</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2007</year>
          <volume>363</volume>
          <fpage>971</fpage>
          <lpage>977</lpage>
          <pub-id pub-id-type="pmid">17927961</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raschle</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA repair. Proteomics reveals dynamic assembly of repair complexes during bypass of DNA cross-links</article-title>
          <source>Science</source>
          <year>2015</year>
          <volume>348</volume>
          <fpage>1253671</fpage>
          <pub-id pub-id-type="pmid">25931565</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cdt2-mediated XPG degradation promotes gap-filling DNA synthesis in nucleotide excision repair</article-title>
          <source>Cell Cycle</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>1103</fpage>
          <lpage>1115</lpage>
          <pub-id pub-id-type="pmid">25483071</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almeida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ryser</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Obarzanek-Fojt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hohl</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The TRAF-interacting protein (TRIP) is a regulator of keratinocyte proliferation</article-title>
          <source>J Invest Dermatol</source>
          <year>2011</year>
          <volume>131</volume>
          <fpage>349</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">21068752</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Branzei</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Foiani</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Maintaining genome stability at the replication fork</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>208</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="pmid">20177396</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>HA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TRIP/NOPO E3 ubiquitin ligase promotes ubiquitylation of DNA polymerase eta</article-title>
          <source>Development</source>
          <year>2014</year>
          <volume>141</volume>
          <fpage>1332</fpage>
          <lpage>1341</lpage>
          <pub-id pub-id-type="pmid">24553286</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bienko</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of translesion synthesis DNA polymerase eta by monoubiquitination</article-title>
          <source>Mol Cell</source>
          <year>2010</year>
          <volume>37</volume>
          <fpage>396</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">20159558</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehmann</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>McGibbon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Xeroderma pigmentosum</article-title>
          <source>Orphanet J Rare Dis</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>70</fpage>
          <pub-id pub-id-type="pmid">22044607</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masutani</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>399</volume>
          <fpage>700</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">10385124</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Kondratick</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>hRAD30 mutations in the variant form of xeroderma pigmentosum</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>285</volume>
          <fpage>263</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="pmid">10398605</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Despras</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Daboussi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hyrien</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Marheineke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kannouche</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>ATR/Chk1 pathway is essential for resumption of DNA synthesis and cell survival in UV-irradiated XP variant cells</article-title>
          <source>Hum Mol Genet</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>1690</fpage>
          <lpage>1701</lpage>
          <pub-id pub-id-type="pmid">20123862</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The role of RPA2 phosphorylation in homologous recombination in response to replication arrest</article-title>
          <source>Carcinogenesis</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>994</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="pmid">20130019</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Gingras</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Durocher</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint</article-title>
          <source>EMBO Rep</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>1019</fpage>
          <lpage>1026</lpage>
          <pub-id pub-id-type="pmid">18758438</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chowdhury</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication</article-title>
          <source>Mol Cell</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>33</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">18614045</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chowdhury</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair</article-title>
          <source>Mol Cell</source>
          <year>2005</year>
          <volume>20</volume>
          <fpage>801</fpage>
          <lpage>809</lpage>
          <pub-id pub-id-type="pmid">16310392</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress</article-title>
          <source>Mol Cell Biol</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>5696</fpage>
          <lpage>5709</lpage>
          <pub-id pub-id-type="pmid">19704001</pub-id>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>McKeon</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage</article-title>
          <source>Cell</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>727</fpage>
          <lpage>735</lpage>
          <pub-id pub-id-type="pmid">9182760</pub-id>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soria</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Polo</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Almouzni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prime, repair, restore: the active role of chromatin in the DNA damage response</article-title>
          <source>Mol Cell</source>
          <year>2012</year>
          <volume>46</volume>
          <fpage>722</fpage>
          <lpage>734</lpage>
          <pub-id pub-id-type="pmid">22749398</pub-id>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lancaster</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Knoblich</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Spindle orientation in mammalian cerebral cortical development</article-title>
          <source>Curr Opin Neurobiol</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>737</fpage>
          <lpage>746</lpage>
          <pub-id pub-id-type="pmid">22554882</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lessel</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features</article-title>
          <source>Nat Genet</source>
          <year>2014</year>
          <volume>46</volume>
          <fpage>1239</fpage>
          <lpage>1244</lpage>
          <pub-id pub-id-type="pmid">25261934</pub-id>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conlon</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Raff</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Size control in animal development</article-title>
          <source>Cell</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>235</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">9988218</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bicknell</surname>
              <given-names>LS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in the pre-replication complex cause Meier-Gorlin syndrome</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>356</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="pmid">21358632</pub-id>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bicknell</surname>
              <given-names>LS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in ORC1, encoding the largest subunit of the origin recognition complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>350</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">21358633</pub-id>
        </element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guernsey</surname>
              <given-names>DL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>360</fpage>
          <lpage>364</lpage>
          <pub-id pub-id-type="pmid">21358631</pub-id>
        </element-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murga</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>891</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="pmid">19620979</pub-id>
        </element-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooke</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Dizdaroglu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lunec</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Oxidative DNA damage: mechanisms, mutation, and disease</article-title>
          <source>FASEB J</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>1195</fpage>
          <lpage>1214</lpage>
          <pub-id pub-id-type="pmid">12832285</pub-id>
        </element-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langevin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Crossan</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Rosado</surname>
              <given-names>IV</given-names>
            </name>
            <name>
              <surname>Arends</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>475</volume>
          <fpage>53</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">21734703</pub-id>
        </element-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frank</surname>
              <given-names>KM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway</article-title>
          <source>Mol Cell</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>993</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="pmid">10911993</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ref-list>
      <title>METHODS-ONLY REFERENCES</title>
      <ref id="R54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in PLK4, encoding a master regulator of centriole biogenesis, cause microcephaly, growth failure and retinopathy</article-title>
          <source>Nat Genet</source>
          <year>2014</year>
          <volume>46</volume>
          <fpage>1283</fpage>
          <lpage>1292</lpage>
          <pub-id pub-id-type="pmid">25344692</pub-id>
        </element-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keupp</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in WNT1 cause different forms of bone fragility</article-title>
          <source>Am J Hum Genet</source>
          <year>2013</year>
          <volume>92</volume>
          <fpage>565</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="pmid">23499309</pub-id>
        </element-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Purcell</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>
          <source>Am J Hum Genet</source>
          <year>2007</year>
          <volume>81</volume>
          <fpage>559</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="pmid">17701901</pub-id>
        </element-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>PK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Directional dominance on stature and cognition in diverse human populations</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>523</volume>
          <fpage>459</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">26131930</pub-id>
        </element-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McQuillan</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Runs of homozygosity in European populations</article-title>
          <source>Am J Hum Genet</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>359</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">18760389</pub-id>
        </element-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polo</surname>
              <given-names>SE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair</article-title>
          <source>Mol Cell</source>
          <year>2012</year>
          <volume>45</volume>
          <fpage>505</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">22365830</pub-id>
        </element-citation>
      </ref>
      <ref id="R60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Despras</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Delrieu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Garandeau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ahmed-Seghir</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kannouche</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Regulation of the specialized DNA polymerase eta: revisiting the biological relevance of its PCNA- and ubiquitin-binding motifs</article-title>
          <source>Environ Mol Mutagen</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>752</fpage>
          <lpage>765</lpage>
          <pub-id pub-id-type="pmid">23076824</pub-id>
        </element-citation>
      </ref>
      <ref id="R61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Elledge</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>MDC1 is a mediator of the mammalian DNA damage checkpoint</article-title>
          <source>Nature</source>
          <year>2003</year>
          <volume>421</volume>
          <fpage>961</fpage>
          <lpage>966</lpage>
          <pub-id pub-id-type="pmid">12607005</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>Mutations in <italic>TRAIP</italic> cause primordial dwarfism</title>
        <p>(<bold>a</bold>) Mutations identified in <italic>TRAIP</italic>. Top, schematic of <italic>TRAIP</italic> gene structure; middle, TRAIP protein structure; bottom, sequence electropherograms demonstrating (middle, right panels) homozygous nonsense mutations in Patient 1 (P1) and Patient 2 (P2) and (left) a homozygous missense mutation, Arg18Cys in Patient 3 (P3). (<bold>b</bold>) A physiochemically similar residue is present at codon 18 in all vertebrates. Sequence alignments of <italic>Homo sapiens, Pan troglodytes, Mus musculus, Gallus gallus, Xenopus tropicalis</italic> and <italic>Danio rerio</italic> using Clustal W. (<bold>c</bold>) Patients with TRAIP mutations have prenatal onset severe growth failure with disproportionate microcephaly. Birth weight (BWGT), current height (HGT) and current head circumference (OFC) plotted as z-scores (standard deviations from population mean for age and sex). 97.5% of general population will lie above the dashed line at â2 S.D. Black bars indicate mean values. (<bold>d</bold>) Cerebral cortical size is markedly reduced with simplification of gyral folding. MRI T2-weighted sagittal and axial images of P3 (age 3 years) compared with control scans of a healthy child (age 3 years 1 month). Scale bar, 2 cm. (<bold>e</bold>) Photographs of affected individuals with <italic>TRAIP</italic> mutations demonstrating facial similarities, including an elongated narrow face and micrognathia. Informed consent to publish photographs was obtained from families.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <title>TRAIP mutations result in reduced cellular levels of TRAIP protein</title>
        <p>(<bold>a</bold>) The Arg185* mutation severely reduces <italic>TRAIP</italic> transcript levels in P1 and P2 patient cell lines. RT-PCR using primers in 5â² and 3â² UTR to amplify <italic>TRAIP</italic> transcripts in primary fibroblasts and lymphoblastoid cell lines (LCLs) demonstrates marked decrease in full length <italic>TRAIP</italic> transcript, consistent with nonsense-mediated decay. Additional low intensity PCR products are evident, that represent alternatively spliced transcripts, confirmed by subcloning and Sanger sequencing (lower panels). These include transcripts, which through omission of exon 7, or exons 6, 7 and 8, retain an open reading frame and result in protein products with small internal deletions. Loading control, <italic>GAPDH</italic>. (<bold>b</bold>) TRAIP protein levels are reduced in patients with Arg185* and the Arg18Cys mutations. Immunoblotting with an affinity purified rabbit anti-TRAIP antibody raised against recombinant TRAIP protein demonstrates reduced levels of the 53 kDa TRAIP protein in P3, and marked depletion in P1 and P2 where protein is only detectable on prolonged exposure (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>). Loading controls, actin and vinculin.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <title>TRAIP localizes to sites of UV-induced DNA damage</title>
        <p>(<bold>a</bold>) TRAIP localizes to DNA damage sites induced by UV laser microirradiation both in the absence and presence of pre-treatment with BrdU as a damage sensitizer. Representative images, before and after UV laser microirradiation. Scale bar, 5 Î¼m. (<bold>b</bold>) GFP-TRAIP colocalizes with Î³H2AX and with RFP-PCNA at sites of UV laser-induced damage. Representative images of UV laser-irradiated GFP-TRAIP expressing cells immunostained for Î³H2AX (pre-sensitized with BrdU) or co-expressing RFP-PCNA (no BrdU pre-treatment) as indicated. Scale bar, 5 Î¼m. (<bold>c</bold>, <bold>d</bold>) GFP-TRAIP is detected by a Proximity Ligation Assay (PLA) in close proximity to PCNA, an association enhanced after UV-induced damage. (<bold>c</bold>) Representative images of PLA signals/nucleus in doxycycline-inducible GFP-TRAIP HeLa cells before and after damage with 25 J/m<sup>2</sup> UV-C. Scale bar, 5 Î¼m. (<bold>d</bold>) Quantification of PLA signals/nucleus. Box plots, center line denote mean values, box 25/75 %, whiskers 5/95 %, data pooled from n=2 independent experiments, n&gt;65 data points per condition per experiment; Mann Whitney rank sum test: *** p&lt;0.001. (<bold>e</bold>) TRAIP accumulates at sites of localized UV damage, colocalising with RPA and Î³H2AX. Representative immunofluorescence images of MRC5 cells transfected with GFP-TRAIP or GFP alone after UV-C irradiation through 3 Î¼m microfilters. Scale bar, 5 Î¼m.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0003"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <title>TRAIP is required for UV-induced RPA2 and H2AX phosphorylation during S-phase</title>
        <p>(<bold>a</bold>) Phosphorylation of downstream ATR substrates is unaffected by TRAIP depletion. HeLa cells were transfected with RNAi against TRAIP or luciferase (control). After 72h, cells were UV-C treated, before harvesting at indicated times. Cell lysates were analyzed by Western blot as indicated. (<bold>b</bold>, <bold>c</bold>) TRAIP loss reduces RPA2 phosphorylation and histone H2AX phosphorylation (Î³H2AX) in response to UV. HeLa cells transfected with TRAIP and control siRNAs (<bold>b</bold>) or primary patient fibroblasts (<bold>c</bold>) were UV-C treated, harvested and immunoblotted as indicated. (<bold>d</bold>, <bold>e</bold>) Quantification of pS4/S8-RPA2 (<bold>d</bold>) and Î³H2AX (<bold>e</bold>) in primary fibroblasts after UV. Chemiluminescence from Western blots quantified using ImageQuant. Mean Â± SEM, n=3 experiments; values normalized to total RPA2 signal; two-way ANOVA across all time points: *** p&lt;0.001, ** p&lt;0.01. (<bold>f</bold>) Retroviral complementation with wild-type TRAIP rescues impaired phosphorylation of RPA2 and H2AX after UV-C irradiation in TRAIP<sup>Arg185*</sup> cells. Fibroblasts derived from P2<sup>Arg185*</sup> were immortalized with hTERT, denoted P2<sup>TERT</sup>; and reconstituted with pMSCV-TRAIP, P2<sup>TERT+TRAIP</sup>. (<bold>g</bold>) TRAIP is required for optimal RPA2 and H2AX phosphorylation in S-phase. P2<sup>TERT</sup> and P2<sup>TERT+TRAIP</sup> cells were irradiated with 15 J/m<sup>2</sup> UV-C, labeled with EdU for 4 h, pre-extracted, fixed and co-stained for pS4/S8-RPA2 or Î³H2AX, EdU and DAPI. Representative images of immunofluorescence staining of pS4/S8-RPA2 (left), quantification of pS4/S8-RPA2 (middle) and Î³H2AX (right) signal integrated density in EdU-positive and EdU-negative cells. Mean Â± SEM for n=3 experiments, values normalized to P2<sup>TERT+TRAIP</sup>; Studentâs <italic>t</italic>-test: *p&lt;0.05; ***p&lt;0.001. Scale bar, 10 Î¼m.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0004"/>
    </fig>
    <fig id="F5" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <title>Impaired growth and cell cycle progression in TRAIP deficient cells</title>
        <p>(<bold>a</bold>) TRAIP mutations impair cell proliferation. Cell numbers of passage-matched primary fibroblast cell lines derived from patients or controls were determined over 17 days to establish growth rates. Mean Â± SEM for n=3 experiments; fold growth relative to day 0. (<bold>b</bold>) Complementation with wild-type TRAIP rescues the slow growth phenotype of TRAIP<sup>Arg185*</sup> cells. P2<sup>TERT</sup> fibroblasts were reconstituted with pMSCV-vector only or pMSCV-TRAIP. Growth rates of passage-matched cell lines were analyzed over 18 days. Mean Â± SEM for n=3 experiments; fold growth relative to day 0. (<bold>c</bold>) Doubling times of fibroblast cells from (<bold>a</bold>) and (<bold>b</bold>). Mean Â± SEM for n=3 experiments; Studentâs <italic>t</italic>-test: *p&lt;0.05; **p&lt;0.01. (<bold>d</bold>) TRAIP-depleted cells exhibit delayed S/G2 phase progression. HeLa cells were transfected with RNAi against TRAIP or luciferase (Luc) control. 72h later cells were pulse labeled with 10 Î¼M BrdU for 30 min before washing out and replacing with fresh media. At indicated times, cells were harvested, fixed and prepared for flow cytometry. Left, Western blots of RNAi for TRAIP or control Luc demonstrate effective TRAIP depletion. Middle, representative images of gating used in analysis of flow cytometry data. Right, quantification of the relative number of cells with 4n content; fold change relative to 0h. Mean Â± SEM, n=4 experiments. Fold change relative to 0h; two-way ANOVA across all time points: ** p&lt;0.01.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0005"/>
    </fig>
    <fig id="F6" orientation="portrait" position="float">
      <label>Figure 6</label>
      <caption>
        <title>Replication fork stalling is increased following UV-induced DNA damage in TRAIP patient cells</title>
        <p>(<bold>a</bold>) First label termination events (representing elevated replication fork stalling) are increased after UV irradiation in TRAIP patient fibroblasts. Top left panel, schematic of the experimental plan. Bottom left panel, representative images of ongoing or stalled replication forks and new origin firing from DNA fiber spreads of primary fibroblasts. Right panel, quantification of ongoing forks, 2<sup>nd</sup> label only (new origin firing) and 1<sup>st</sup> label termination (fork stalling) structures in fibroblast cells. Mean Â± SD, n=3 independent experiments, &gt;400 structures per cell line per experiment quantified. Studentâs <italic>t</italic>-test: *p&lt;0.05; **p&lt;0.01; ns, not significant. (<bold>b</bold>, <bold>c</bold>) Substantial fork asymmetry is seen in UV-treated patient cells. (<bold>b</bold>) Representative images of DNA fibers from controls (Con1, Con2) and patient fibroblasts (P2, P3) after 30 J/m<sup>2</sup> UV treatment. (<bold>c</bold>) Quantification of replication fork asymmetry. Ratio of left/right fork length; mean ratio for each cell line is indicated in italics; Mann Whitney Rank sum test: ***p&lt;0.001; ns, not significant. Data points pooled from n=2 independent experiments, &gt;50 structures per cell line per experiment quantified.</p>
      </caption>
      <graphic xlink:href="emss-65773-f0006"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="landscape">
      <label>Table 1</label>
      <caption>
        <title>Clinical summary of individuals with <italic>TRAIP</italic> mutations</title>
      </caption>
      <table frame="hsides" rules="none">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Individual</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Gender</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Consanguinity</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Ancestry</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Nucleotide<break/>mutation</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Protein<break/>alteration</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Gestation<break/>(weeks)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">BWT<break/>(kg)<break/><italic>SD</italic><hr/></th>
            <th align="left" valign="top" rowspan="1" colspan="1">Age<break/>(years)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Height<break/>(cm)<break/><italic>SD</italic><hr/></th>
            <th align="left" valign="top" rowspan="1" colspan="1">OFC<break/>(cm)<break/><italic>SD</italic><hr/></th>
            <th align="left" valign="top" rowspan="1" colspan="1">Karyotype</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Craniofacial<break/>features</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Clinical synopsis</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">P1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Italian</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.553C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">p.Arg185*</td>
            <td align="left" valign="top" rowspan="1" colspan="1">37</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.95<break/><italic>â2.7</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">85.9<break/><italic>â5.4</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">44<break/><italic>â6.5</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">46, XX</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Microcephaly,<break/>scaphocephaly,<break/>long narrow<break/>face,<break/>micrognathia.</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IUGR; recurrent severe lower<break/>respiratory tract infections;<break/>delayed speech, 2 deceased<break/>siblings with similar<break/>phenotypes.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">P2</td>
            <td align="left" valign="top" rowspan="1" colspan="1">M</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">English</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.553C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">p.Arg185*</td>
            <td align="left" valign="top" rowspan="1" colspan="1">32</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.2<break/><italic>â2.2</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">7</td>
            <td align="left" valign="top" rowspan="1" colspan="1">103.5<break/><italic>â3.9</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">40.7<break/><italic>â8.3</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">46, XY</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Microcephaly,<break/>scaphocephaly,<break/>long narrow<break/>face,<break/>micrognathia.</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IUGR; recurrent severe lower<break/>respiratory tract infections;<break/>moderate global<break/>developmental delay;<break/>hypertrichosis.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">P3</td>
            <td align="left" valign="top" rowspan="1" colspan="1">M</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3<sup>rd</sup> cousin</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Turkish</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.52C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">p.Arg18Cys</td>
            <td align="left" valign="top" rowspan="1" colspan="1">40</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.75<break/><italic>â2.9</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">3</td>
            <td align="left" valign="top" rowspan="1" colspan="1">80<break/><italic>â4.6</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">40.1<break/><italic>â8.1</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">46, XY</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Microcephaly,<break/>long narrow<break/>face,<break/>micrognathia.</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IUGR; asthma; mild global<break/>developmental delay.</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <p id="P49">All parents were demonstrated to be heterozygote carriers of the mutations identified, confirming appropriate segregation within the family. Age is shown in years at time of measurements. BWT, birth weight; SD, standard deviation from the population mean for age and sex; OFC, occipital frontal circumference; F, female; M, male; NC, non-consanguineous; IUGR, intrauterine growth restriction.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>